Cerus Corporation will attend the 2025 AABB Annual Meeting in San Diego, California, from October 25 to October 28. The company will host an industry workshop on the benefits of pathogen reduced cryoprecipitated fibrinogen complex, known as INTERCEPT Fibrinogen Complex, and present eighteen related abstracts highlighting the impact of its technologies on blood safety and availability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021249458) on October 21, 2025, and is solely responsible for the information contained therein.